rivaroxaban우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42493732
Disagreement in rivaroxaban dosing between Cockcroft-Gault and eGFR equations in nonvalvular atrial fibrillation: a statewide analysis.
Disagreement in rivaroxaban dosing between Cockcroft-Gault and eGFR equations in nonvalvular atrial fibrillation: a statewide analysis.
- 저자
- Amina Ammar, Stephanie Edwin, Geoffrey D Barnes, Scott Kaatz, Deborah DeCamillo, Xiaowen Kong
- 저널
- Journal of thrombosis and thrombolysis
- 공개일
- 2026 Jul 23
- 연구 유형
- 기타
- DOI
- 10.1007/s11239-026-03367-4
문헌 요약
Rivaroxaban dosing for nonvalvular atrial fibrillation (NVAF) is based on Cockcroft-Gault creatinine clearance using actual body weight (CG-CrCl-ABW) per FDA labeling. Recent recommendations support utilizing the race-free CKD-EPI 2021 equation for estimating kidney function. However, it is unknown whether substituting estimated glomerular filtration rate…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.